Corcept Therapeutics (CORT) PT Raised to $29 at Truist Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $87.23 +0.11%
Rating Summary:
8 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Rating Summary:
8 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Join SI Premium – FREE
Truist Securities analyst Joon Lee raised the price target on Corcept Therapeutics (NASDAQ: CORT) to $29.00 (from $26.00) while maintaining a Hold rating.
You May Also Be Interested In
- Corcept's Lifyorli combo shows PFS gains in ovarian cancer trial
- Sandfire Resources NL (SFR:AU) (SNDFY) PT Lowered to AUD25 at Canaccord
- PrairieSky Royalty Ltd (PSK:CN) (PREKF) PT Raised to Cdn$40 at TD Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
